Clinical Trial Update: Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating chemotherapy with ATRA with or without gemtuzumab ozogamicin in AML patients with NPM1 mutation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• All-trans retinoic acid (ATRA) (all-trans retinoic acid)
• Gemtuzumab ozogamicin (gemtuzumab ozogamicin)

Snippet

Sponsor: University of Ulm | Conditions: Acute Myeloid Leukemia | Phase 3 | Status: COMPLETED